Clinical Trial NCT03531255
Trial
Apellis – APL2-307
Clinical trial ID
NCT03531255
Drug name
APL-2 Pegcetacoplan
Company:
Apellis
Drug trade name
Empaveli® Aspaveli®
Phase of study
3
Current status
Active, not recruiting
Start
08/2018
Substance
Cyclopeptide
Research question
Long-term evaluation
Delivery method of drug
s.c.
Frequency
2 x weekly
Clinical trial locations
tralia Belgium Bulgaria Canada France Germany Hong Kong Japan Malaysia Russia Serbia Singapore South Korea Spain Thailand UK USA